Looking forward to 2022, the pharmaceutical equipment industry will press the "shift button"!

Medicine is a rigid demand.
In recent years, the total global medical expenditure has been increasing.
In 2019, it was close to 1.
3 trillion U.
S.
dollars.
It is expected that the market will maintain a growth rate of about 5% by 2023, and the global total medical expenditure will exceed 1.
5 trillion U.
S.
dollars.
Behind the rapid growth of this set of data, it has a certain relationship with the continuous approval and application of innovative drugs, as well as the market access and use expansion of emerging market drugs
.
In China’s pharmaceutical market, in recent years, with the continuous improvement of the living standards of our residents, the intensified population aging, and the promotion of a series of favorable pharmaceutical innovation and development policies, the continuous growth of R&D investment by local pharmaceutical companies has led to the rapid growth of domestic innovative drugs and emerging drugs.
Development, the entire pharmaceutical market has also ushered in a period of rapid development.
In 2019, the market size has reached about 1.
64 trillion yuan.
According to the same growth rate as in previous years, China's pharmaceutical market will reach 1.
75 trillion yuan in 2020 and reach 2.
13 in 2023.
Around trillion yuan
.
It can be seen that the market space of China's pharmaceutical industry is broad in the future
.
Pharmaceutical equipment (picture source: Pharmaceutical Network) Pharmaceutical equipment is the upstream of medicine.
In recent years, the growth rate of fixed assets of pharmaceutical companies has maintained rapid growth, which has also brought development opportunities to the pharmaceutical equipment industry
.
The pharmaceutical equipment industry is currently in a period of strategic transformation, gradually transforming from a single equipment supplier to a supplier that can provide technical solutions; from the imitation stage to the combination of imitation and innovation and the realization of independent innovation
.
The year 2022 is regarded by the industry as a year for the accelerated harvest of Chinese innovative drugs and an important year for domestic innovative drugs to be launched overseas
.
In this context, pharmaceutical companies will further increase their requirements for equipment production capacity and stability
.
The pharmaceutical equipment industry urgently needs to press the "shift button" to upgrade from low-end to mid-to-high-end, and accelerate the application of integration, automation, informatization, and intelligent technologies
.
At present, the pharmaceutical equipment giants represented by Chutian Technology, Tofflon Technology, Canaan Technology, etc.
have already deployed in the field of high-end pharmaceutical equipment, speeding up the promotion of intelligent manufacturing, and helping the overall "intelligent manufacturing" level of the pharmaceutical equipment industry. .
For example, Chutian Technology has successfully developed some intelligent pharmaceutical production robots and their production lines using automation and information technology, and is transforming into an EPC service provider that creates an overall solution for the pharmaceutical industry 4.
0 smart factory
.
Tofflon is striding towards high-end manufacturing and intelligent manufacturing through continuous technological upgrading and innovation.
Based on sterile injection equipment, strengthening API equipment, deploying bioengineering product equipment and oral solid preparation equipment, and striving to become a comprehensive pharmaceutical in the future Giant equipment service provider
.
Canaan Technology is a domestic solid preparation smart factory overall solution provider.
The company stated on the interactive platform in December that the company has continuous R&D capabilities to meet customer needs.
The company relies on its own R&D center, intelligent manufacturing research institute, pharmaceutical research institute and Scientific research institutions cooperate in research and development, and the company's products are highly intelligent, which can meet customers' multi-level and complex needs for pharmaceutical production lines, such as informatization, automation, quality control, logistics traceability, remote monitoring, and energy saving and emission reduction
.
What needs to be noticed is that at present, most of China's pharmaceutical machinery companies are mainly small and medium-sized enterprises.
These companies have limited capabilities, low R&D investment, lack of funds, shortage of talents, and low level of corporate management.
They have outstanding shortcomings, so they are moving towards high-end There are still certain challenges in the direction transformation
.
However, the policy has also paid attention to the development of small and medium-sized enterprises, including pharmaceutical machinery enterprises, or to provide motivation and support for the advancement of small and medium-sized enterprises
.
Recently, the Ministry of Industry and Information Technology issued the "Fourteenth Five-Year Plan to Promote the Development of Small and Medium-sized Enterprises", striving to achieve steady improvement in overall development quality of small and medium-sized enterprises by 2025, significant improvement in innovation and specialization, significantly improved management and comprehensive service supply capabilities Upgrade and further optimize the development environment
.
The plan clearly states that the "Small and Medium-sized Enterprise Digitalization Promotion Project" will be implemented to give play to the important role of small and medium-sized enterprises as the main force in the development of the digital economy.
Specifically, three aspects of work will be carried out, including: boosting the digital development of small and medium-sized enterprises, networked collaboration, and intelligent upgrades.
Promote the digital transformation of small and medium-sized enterprises in three aspects; actively promote the development of digital industrialization of small and medium-sized enterprises; continue to consolidate the foundation of digital services for small and medium-sized enterprises
.
Generally speaking, the new era has arrived.
Looking forward to 2022, pharmaceutical equipment industry companies should seize the opportunity, actively embrace digital and intelligent technologies, and accelerate their development towards the high-end direction
.